$BIAF
bioAffinity Technologies, Inc. Stock $biaf

$biaf Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017083 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$19.74K	$921.00	$0.00
YoY Change	1406.72%
Cost Of Revenue	$1.234K	$87.00
YoY Change	722.67%
Gross Profit	$18.50K	$834.00
YoY Change	1495.17%
Gross Profit Margin	93.75%	90.55%
Selling, General & Admin	$1.426M	$1.170M	$352.5K
YoY Change	308.25%	231.77%	88.52%
% of Gross Profit	7708.98%	140234.89%
Research & Development	$335.1K	$369.6K	$374.5K
YoY Change	-0.22%	-1.31%	23.11%
% of Gross Profit	1811.09%	44318.59%
Depreciation & Amortization	$21.00K	$22.00K	$1.040K
YoY Change	1919.23%	2015.38%	-36.59%
% of Gross Profit	113.49%	2637.89%
Operating Expenses	$1.797M	$1.559M	$727.0K
YoY Change	162.21%	114.4%	48.01%
Operating Profit	-$1.778M	-$1.558M	-$727.0K
YoY Change	159.95%	114.29%
Interest Expense	$1.360K	$37.00K	-$742.8K
YoY Change	-99.65%	-104.98%	233.07%
% of Operating Profit
Other Income/Expense, Net	$42.76K	$37.00K	-$1.147M
YoY Change		-103.23%
Pretax Income	-$1.736M	-$1.521M	-$1.470M
YoY Change	1871.14%	3.48%	105.8%
Income Tax	$4.587K	$11.82K	$2.160K
% Of Pretax Income
Net Earnings	-$1.740M	-$1.533M	-$1.472M
YoY Change	1876.35%	4.13%	105.54%
Net Earnings / Revenue	-8816.36%	-166426.71%
Basic Earnings Per Share	-$0.20	-$0.18	-$0.55
Diluted Earnings Per Share	-$0.20	-$0.18	-$981.3K
COMMON SHARES
Basic Shares Outstanding	8.519M shares	8.463M shares	2.681M shares
Diluted Shares Outstanding	8.521M shares	8.434M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.279M	$9.769M	$1.028M
YoY Change	3761.56%	850.27%
Cash & Equivalents	$8.300M	$9.800M	$1.028M
Short-Term Investments
Other Short-Term Assets	$279.7K	$441.1K	$64.93K
YoY Change	181.45%	579.39%
Inventory	$10.10K	$11.34K	$5.800K
Prepaid Expenses
Receivables	$90.23K	$11.03K	$6.860K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.659M	$10.23M	$1.106M
YoY Change	2546.05%	825.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$207.4K	$225.1K	$3.590K
YoY Change	8032.43%	6169.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.920K	$6.920K	$243.8K
YoY Change	-98.87%	-97.16%
Total Long-Term Assets	$214.3K	$232.0K	$247.4K
YoY Change	-65.07%	-6.23%
TOTAL ASSETS
Total Short-Term Assets	$8.659M	$10.23M	$1.106M
Total Long-Term Assets	$214.3K	$232.0K	$247.4K
Total Assets	$8.873M	$10.46M	$1.353M
YoY Change	843.24%	673.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$174.4K	$146.5K	$247.7K
YoY Change	-70.19%	-40.84%
Accrued Expenses	$515.7K	$481.3K	$1.860M
YoY Change	-73.89%	-74.12%
Deferred Revenue
YoY Change
Short-Term Debt	$42.33K	$168.4K	$11.78M
YoY Change	-99.62%	-98.57%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$775.2K	$796.3K	$13.88M
YoY Change	-94.33%	-94.26%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$149.7K
YoY Change		-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$149.7K
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$775.2K	$796.3K	$13.88M
Total Long-Term Liabilities	$0.00	$0.00	$149.7K
Total Liabilities	$775.2K	$796.3K	$14.03M
YoY Change	-94.33%	-94.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$39.90M	-$38.20M
YoY Change
Common Stock	$59.89K	$59.24K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.098M	$9.668M	-$12.68M
YoY Change
Total Liabilities & Shareholders Equity	$8.873M	$10.46M	$1.353M
YoY Change	843.24%	673.42%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.740M	-$1.533M	-$1.472M
YoY Change	1876.35%	4.13%	105.54%
Depreciation, Depletion And Amortization	$21.00K	$22.00K	$1.040K
YoY Change	1919.23%	2015.38%	-36.59%
Cash From Operating Activities	-$1.360M	-$1.529M	-$634.0K
YoY Change	261.55%	141.19%	61.5%
INVESTING ACTIVITIES
Capital Expenditures	$3.870K	$32.31K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$3.870K	-$32.31K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-126.1K	-$83.32K	301.4K
YoY Change	-71.18%	-127.65%	-43.91%
NET CHANGE
Cash From Operating Activities	-1.360M	-$1.529M	-634.0K
Cash From Investing Activities	-3.870K	-$32.31K
Cash From Financing Activities	-126.1K	-$83.32K	301.4K
Net Change In Cash	-1.490M	-$1.645M	-332.6K
YoY Change	83.12%	394.47%	-329.85%
FREE CASH FLOW
Cash From Operating Activities	-$1.360M	-$1.529M	-$634.0K
Capital Expenditures	$3.870K	$32.31K
Free Cash Flow	-$1.364M	-$1.561M	-$634.0K
YoY Change		146.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001712762
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2022Q1	us-gaap	Gross Profit GrossProfit		usd
CY2023Q1	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable		usd
CY2023Q1	us-gaap	Accretion Expense AccretionExpense		usd
CY2023Q1	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable		usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet		usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q1	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt		usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q1	BIAF	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts		usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	BIAF	Fair Value Of Warrants Issued FairValueOfWarrantsIssued		usd
CY2023Q1	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-41463
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	bioAffinity Technologies, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5211056
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	22211 W. Interstate 10
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1206
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Antonio
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78257
CY2023Q1	dei	City Area Code CityAreaCode	(210)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	698-5334
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8518981	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9769088	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11413759	usd
CY2023Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	11027	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	10489	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	11335	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5540	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	441132	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531899	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	10232582	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11961687	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	225067	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214438	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6920	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6000	usd
CY2023Q1	us-gaap	Assets Assets	10464569	usd
CY2022Q4	us-gaap	Assets Assets	12182125	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	146537	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	345042	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	481336	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	541894	usd
CY2023Q1	us-gaap	Loans Payable Current LoansPayableCurrent	168430	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	251746	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	796303	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1138682	usd
CY2023Q1	us-gaap	Liabilities Liabilities	796303	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1138682	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285714	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285714	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8463052	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8463052	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8381324	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8381324	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	59241	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	58669	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47809283	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	47652242	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38200258	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36667468	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9668266	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10464569	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12182125	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	921	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	87	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	834	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	369617	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	279848	usd
CY2023Q1	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	19628	usd
CY2022Q1	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	52503	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1169559	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	394692	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1558804	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	727043	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1557970	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-727043	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	36999	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1147012	usd
CY2022Q1	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	404194	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1520971	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1469861	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11819	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2159	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1532790	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1472020	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8433689	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2681221	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	157613	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1532790	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9668266	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15790719	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-15790719	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	106047	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	213942	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	217973	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1472020	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-16724777	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-16724777	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1532790	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1472020	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21685	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1039	usd
CY2022Q1	us-gaap	Accretion Expense AccretionExpense	978217	usd
CY2022Q1	BIAF	Fair Value Adjustments On Convertible Notes Payable FairValueAdjustmentsOnConvertibleNotesPayable	404194	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	157613	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	106047	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	538	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	5331	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5795	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5803	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-89847	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11143	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-198505	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	17284	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-60558	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-29649	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	169300	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1529041	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-633967	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32314	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32314	usd
CY2023Q1	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	83316	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	475000	usd
CY2022Q1	BIAF	Payment Of Deferred Offering Costs PaymentOfDeferredOfferingCosts	117986	usd
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	55651	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-83316	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	301363	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1644671	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-332604	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11413759	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1360638	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9769088	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1028034	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	11819	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2159	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1655	usd
CY2022Q1	BIAF	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	217973	usd
CY2022Q1	BIAF	Beneficial Conversion Feature For Bridge Notes BeneficialConversionFeatureForBridgeNotes	213942	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38200000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9800000	usd
CY2023Q1	BIAF	Total Assets Percent TotalAssetsPercent	0.93	pure
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_z0I8v3EazSuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zJH3ThwATV3j">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include: the valuation allowance on the Company’s deferred tax assets; the useful lives of fixed assets; and the fair value of the convertible notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	6000	usd
CY2022Q1	us-gaap	Advertising Expense AdvertisingExpense	3000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5556344	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6209737	shares
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z5pIjxOSVIt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_z6ryzgrtUit4">Reclassifications</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year balances have been reclassified to conform to current year presentation. The Company reclassified patent expenses and annuity costs of approximately $<span id="xdx_907_eus-gaap--FiniteLivedPatentsGross_iI_c20220331__us-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember__srt--RestatementAxis__srt--RestatementAdjustmentMember_zk4bRXjqRzi4" title="Patent and annuity costs">42,000</span> from research and development to selling, general and administrative for the three months ended March 31, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	222742	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	340078	usd
CY2023Q1	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	84077	usd
CY2022Q4	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	72048	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	134313	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	119773	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	441132	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	531899	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	515932	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	483618	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	290865	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	269180	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	225067	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	214438	usd
CY2023Q1	us-gaap	Depreciation Depreciation	22000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	1000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	281085	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	340680	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	131819	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	144440	usd
CY2023Q1	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	58262	usd
CY2022Q4	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	50922	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10170	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5852	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	481336	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	541894	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	26000	usd
CY2022Q1	us-gaap	Payments For Rent PaymentsForRent	13000	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-7 reverse stock split
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285714	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8463052	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8381324	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1100000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	1000000.0	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	157613	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	106047	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	806392	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.33
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	806392	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.33
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y9M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	271298	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	803218	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	4.31
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y8M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	271298	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7142	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.84
CY2022Q1	us-gaap	Share Price SharePrice	4.62
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.639	pure
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0220	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4649952	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4649952	shares

Files In Submission

Name	View Source	Status
0001493152-23-017083-index-headers.html	Edgar Link	pending
0001493152-23-017083-index.html	Edgar Link	pending
0001493152-23-017083.txt	Edgar Link	pending
0001493152-23-017083-xbrl.zip	Edgar Link	pending
biaf-20230331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
biaf-20230331_def.xml	Edgar Link	unprocessable
biaf-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
biaf-20230331_cal.xml	Edgar Link	unprocessable
biaf-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIAF
bioAffinity Technologies, Inc. Stock $biaf

2023 Q2 Form 10-Q Financial Statement

#000149315223017083 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF bioAffinity Technologies, Inc. Stock $biaf

2023 Q2 Form 10-Q Financial Statement

#000149315223017083 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF
bioAffinity Technologies, Inc. Stock $biaf